Administration of hypothalamic-releasing factors is a potential means of correction of the abnormal neuroendocrine function characteristic of CCI. Van den Berghe et a l163 performed a small RCT (n 33) administering GH-releasing peptide-2 (GHRP-2), thyrotropin-releasing hormone (TRH), and gonadotropin-releasing hormone (GnRH) in various combinations, compared to placebo, in primarily CCI male patients. Administration of all 3 hormones resulted in reactivation of the GH, TSH, and LH axes.Treatment with releasing factors instead of pituitary or peripheral hormones has the potential benefit of allowing the body to adjust target hormone levels as needed to prevent overdose and toxicity.This intervention should be considered still investigational, and larger studies are needed to clarify the role of hypothalamic-releasing factors in the treatment of CCI patients.